The COLISTAT is a feed supplement with biological activity against E. coli and other Gram-negative microorganisms.
The mode of action of COLISTAT
In the intestinal microflora of a healthy piglet, the Lactobacilli are dominating. This fact is first of all important from the point of view of antagonic effect on E. coli and also other Gram-positive bacteria. The plant extracts facilitate the growth of Lactobacilli and in this way play a role in maintenance of the microbial equilibrium of the intestines.
The effect of stress in the weaning period combined with the decrease in peristaltic activity makes favorable conditions for the growth of E. coli followed in the same time with reducing of the number of Lactobacilli. The abnormal growth of endopathogenic E. coli strains results in a distribution of microbial equilibrium and as a consequence intestinal inflammations, oedema syndrome may occur due to the toxic effect of endotoxins produced by E. coli strains.
Body weight at the weaning age, from the report of the Veterinary University of Budapest.
Advantages of the use of COLISTAT
Summary of the report of Veterinary University of Budapest
3-5 kg COLISTAT/ 1 ton of complete feed.
The COLISTAT containing feed should be included in the ration starting 2 weeks before the weaning and continuously until 21 day after weaning.
The supplement may be simultaneously used with any other medicament.
In the framework of the Central Hungarian Operational Program (Közép-Magyarországi Operatív Program), Dr. BATA Hungarian Canadian Biotechnology Research Development Ltd. was awarded 97 500 000 HUF of subsidies from EU and domestic central budget sources to develop environmentally friendly, food- safety-precision trace element of premixes for the commercial livestock.
The project’s total budget is 150 million HUF.
Our company completed the project KMOP-1.1.1-07/1-2008-0013 on the 31st May 2011.Continue reading
The Dr. Bata Ltd. won 318.66 million HUF non-refundable funding on the project “Funding for market-oriented research and development”. The investment budget of 480.33 million HUF helped to develop a complex, biotechnology based, acid-resistant, protected NSP enzymproduct development of probiotic effect. Throughout this project the solution was found for the economical and environment friendly treatment and utilization of biological, rich in fiber by-products.Continue reading
In the framework of the Central Hungarian Operational Program, the Dr BATA Hungarian Canadian Biotechnology Research Development Ltd. was awarded 115 million HUF in support of the project "Support for Enterprise Innovation". In the framework of the project, we applied for the development of a herbal combination-based product family against digestive diseases in pigs and help for the market access of the developed product. The total budget of the project was 255.56 million HUF.Continue reading